X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (72) 72
index medicus (37) 37
colorectal cancer (34) 34
humans (33) 33
bevacizumab (24) 24
colorectal neoplasms - drug therapy (24) 24
cancer (22) 22
metastasis (22) 22
chemotherapy (21) 21
male (21) 21
female (20) 20
metastatic colorectal cancer (19) 19
aged (17) 17
colorectal neoplasms - pathology (17) 17
colorectal neoplasms - genetics (15) 15
metastases (15) 15
middle aged (15) 15
antineoplastic combined chemotherapy protocols - therapeutic use (14) 14
neoplasm metastasis (14) 14
survival (14) 14
care and treatment (13) 13
colorectal carcinoma (13) 13
patients (13) 13
research (13) 13
cetuximab (12) 12
genetic aspects (12) 12
prognosis (12) 12
adult (11) 11
colorectal neoplasms - mortality (11) 11
1st-line treatment (10) 10
analysis (10) 10
angiogenesis (10) 10
camptothecin - analogs & derivatives (10) 10
clinical trials (10) 10
single-nucleotide polymorphism (9) 9
treatment outcome (9) 9
aged, 80 and over (8) 8
biomarkers (8) 8
braf (8) 8
disease-free survival (8) 8
mutation (8) 8
panitumumab (8) 8
drug therapy (7) 7
single nucleotide polymorphisms (7) 7
survival analysis (7) 7
alleles (6) 6
antineoplastic agents - therapeutic use (6) 6
article (6) 6
biomarkers, tumor - metabolism (6) 6
cancer patients (6) 6
deoxyribonucleic acid--dna (6) 6
gene expression (6) 6
genes (6) 6
genotype (6) 6
irinotecan (6) 6
open-label (6) 6
oxaliplatin (6) 6
polymorphism (6) 6
polymorphism, single nucleotide (6) 6
ras proteins - genetics (6) 6
retrospective studies (6) 6
usage (6) 6
biomarkers, tumor - genetics (5) 5
camptothecin - administration & dosage (5) 5
camptothecin - therapeutic use (5) 5
cancer therapies (5) 5
cells (5) 5
fluorouracil (5) 5
fluorouracil - administration & dosage (5) 5
fluorouracil - therapeutic use (5) 5
leucovorin - administration & dosage (5) 5
leucovorin - therapeutic use (5) 5
monoclonal antibodies (5) 5
polymerase chain reaction (5) 5
proto-oncogene proteins b-raf - genetics (5) 5
resistance (5) 5
therapy (5) 5
tumors (5) 5
antineoplastic combined chemotherapy protocols - administration & dosage (4) 4
bevacizumab - administration & dosage (4) 4
colon-cancer (4) 4
dna (4) 4
expression (4) 4
gene sequencing (4) 4
genotypes (4) 4
health aspects (4) 4
infusional fluorouracil (4) 4
kras (4) 4
medical prognosis (4) 4
medical research (4) 4
medicine & public health (4) 4
microsatellite instability (4) 4
patient outcomes (4) 4
pharmacogenetics (4) 4
progression-free survival (4) 4
randomized phase-iii (4) 4
ras (4) 4
regorafenib (4) 4
vascular endothelial growth factor (4) 4
5-fluorouracil (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Reviews Gastroenterology & Hepatology, ISSN 1759-5045, 05/2016, Volume 13, Issue 5, pp. 258 - 259
Journal Article
New England Journal of Medicine, ISSN 0028-4793, 06/2016, Volume 374, Issue 22, p. 2183
Journal Article
Cancer journal (Sudbury, Mass.), ISSN 1528-9117, 2016, Volume 22, Issue 3, pp. 156 - 164
In the last 20 years improvements in metastatic colorectal cancer treatment lead to a radical raise of outcomes with median survival reaching now more than 30... 
MSI | colorectal | liquid biopsies | biomarkers | RAF | BRAF | clinical trials
Journal Article
International Journal of Cancer, ISSN 0020-7136, 01/2015, Volume 136, Issue 1, pp. 83 - 90
NRAS mutations occur in 3–5% of colorectal cancer. Differently from KRAS and BRAF mutations, the role of NRAS mutations as prognostic and predictive markers in... 
metastatic colorectal cancer | NRAS | BRAF | KRAS | anti‐EGFR | anti-EGFR | 1ST-LINE TREATMENT | N-RAS | MICROSATELLITE INSTABILITY | KRAS WILD-TYPE | COLON-CANCER | PANITUMUMAB | K-RAS | ONCOLOGY | BRAF MUTATIONS | RAS MUTATIONS | CETUXIMAB PLUS IRINOTECAN | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Prognosis | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | Mutation, Missense | Liver Neoplasms - mortality | DNA Mutational Analysis | Antibodies, Monoclonal, Humanized - pharmacology | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Retrospective Studies | Cetuximab | Liver Neoplasms - secondary | Colorectal Neoplasms - mortality | Antibodies, Monoclonal, Humanized - therapeutic use | Genetic Association Studies | Liver Neoplasms - genetics | Membrane Proteins - genetics | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Disease-Free Survival | Drug Resistance, Neoplasm - genetics | GTP Phosphohydrolases - genetics | Proto-Oncogene Proteins B-raf - genetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Colorectal Neoplasms - pathology | Chemotherapy | Gene mutations | Analysis | Colorectal cancer | Monoclonal antibodies | Genetic aspects | Metastasis | Cancer | Mutation | Medical prognosis | Tumors | Index Medicus
Journal Article
European Journal of Cancer, ISSN 0959-8049, 11/2017, Volume 86, pp. 197 - 206
Trifluridine (FTD) is an active cytotoxic component of the metastatic colorectal cancer (mCRC) drug TAS-102, and thymidine phosphorylase inhibitor (TPI)... 
TAS-102 | Trifluridine | Thymidine phosphorylase inhibitor | Transporter | Metastatic colorectal cancer | THYMIDINE KINASE | METFORMIN | CELLS | SOLID TUMORS | TRIFLUOROTHYMIDINE | NUCLEOSIDE TRANSPORTERS | 5-FLUOROURACIL | ONCOLOGY | OCT2 | RESISTANCE | PHASE-I | Predictive Value of Tests | Colorectal Neoplasms - genetics | Humans | Organic Cation Transporter 2 - metabolism | Male | Antineoplastic Agents - therapeutic use | Trifluridine - pharmacokinetics | Neoplasm Metastasis | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Pharmacogenomic Variants | Female | Antineoplastic Agents - pharmacokinetics | Retrospective Studies | Pharmacogenetics | Organic Cation Transport Proteins - metabolism | Gene Frequency | Japan | Equilibrative Nucleoside Transporter 1 - genetics | Uracil - therapeutic use | Genotype | Treatment Outcome | Equilibrative Nucleoside Transporter 1 - metabolism | California | Pharmacogenomic Testing | Trifluridine - therapeutic use | Disease-Free Survival | Phenotype | Uracil - adverse effects | Trifluridine - adverse effects | Italy | Polymorphism, Single Nucleotide | Colorectal Neoplasms - pathology | Organic Cation Transport Proteins - genetics | Uracil - pharmacokinetics | Organic Cation Transporter 2 - genetics | Drug Combinations | Uracil - analogs & derivatives | Cancer patients | Genes | Colorectal cancer | Nucleosides | Physiological aspects | Genetic research | Genetic aspects | Single nucleotide polymorphisms | Metastasis | Toxicity | Colorectal carcinoma | Cytotoxicity | Thymidine | Single-nucleotide polymorphism | Oct-2 protein | Metastases | Gene sequencing | Training | Thymidine phosphorylase | Genotypes | Deoxyribonucleic acid--DNA | Excretion | Metabolism | Patients | Survival | Phosphorylase | Polymerase chain reaction | Frontotemporal dementia | Polymorphism | DNA sequencing | Cancer | Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2013, Volume 8, Issue 7, pp. e66774 - e66774
Purpose: The potential impact of different SNPs of VEGF/VEGFR pathway on the clinical outcome of mCRC patients receiving bev-containing regimens has been... 
BIOMARKERS | LEUCOVORIN | CLINICAL-TRIAL DESIGNS | POLYMORPHISMS | MULTIDISCIPLINARY SCIENCES | PHASE-3 TRIAL | RESISTANCE | OXALIPLATIN | FLUOROURACIL | GENETIC-VARIATIONS | CHINESE POPULATION | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Colorectal Neoplasms - genetics | Humans | Middle Aged | Neovascularization, Pathologic | Male | Vascular Endothelial Growth Factor A - genetics | Bevacizumab | Vascular Endothelial Growth Factor Receptor-2 - genetics | Neoplasm Metastasis | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Camptothecin - administration & dosage | Adenocarcinoma - genetics | Retrospective Studies | Drug Therapy, Combination | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Gene Expression | Antibodies, Monoclonal, Humanized - therapeutic use | Colorectal Neoplasms - blood supply | Treatment Outcome | Adenocarcinoma - drug therapy | Sequence Analysis, DNA | Adenocarcinoma - blood supply | Survival Analysis | Aged | Polymorphism, Single Nucleotide | Adenocarcinoma - mortality | Care and treatment | Vascular endothelial growth factor | Analysis | Risk factors | Colorectal cancer | Impact prediction | Colorectal carcinoma | Clinical trials | Oncology | Single-nucleotide polymorphism | Metastasis | Cancer therapies | Patients | Metastases | Vascular endothelial growth factor receptors | Angiogenesis | Experimental design | Peripheral blood | Biomarkers | Population | Mathematical models | Deoxyribonucleic acid--DNA | Cancer | Index Medicus | Deoxyribonucleic acid | DNA
Journal Article
Journal Article
British Journal of Cancer, ISSN 0007-0920, 04/2018, Volume 118, Issue 7, pp. 955 - 965
BACKGROUND: Many factors, including histopathologic parameters, seem to influence the prognosis of patients undergoing resection of colorectal cancer liver... 
SURVIVAL | SURGERY | THERAPY | ONCOLOGY | FOLFOXIRI | PATHOLOGICAL RESPONSE | TUMOR RESPONSE | HEPATIC RESECTION | CARCINOMA | CHEMOTHERAPY | Colorectal Neoplasms - surgery | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Male | Liver Neoplasms - mortality | Young Adult | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Oxaliplatin - administration & dosage | Liver Neoplasms - secondary | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Bevacizumab - administration & dosage | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Liver Neoplasms - drug therapy | Liver Neoplasms - surgery | Treatment Outcome | Combined Modality Therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Cetuximab - administration & dosage | Aged | Colorectal Neoplasms - pathology | Deoxycytidine - analogs & derivatives | 5-Fluorouracil | Liver | Colorectal carcinoma | Colorectal cancer | Clinical trials | Metastasis | Parameter sensitivity | Bevacizumab | Metastases | Triplets | Liver cancer | Oxaliplatin | Medical research | Folinic acid | Sensitivity analysis | Regression analysis | Patients | Survival | Irinotecan | Chemotherapy | Antiangiogenics | Pushing | Medical prognosis | Growth patterns | Cancer | Tumors | Index Medicus | Targeted therapies | Colon cancer
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2017, Volume 77, pp. 13 - 20
Abstract Purpose The most frequent bevacizumab-related side-effects are hypertension, proteinuria, bleeding and thromboembolism. To date, there is no biomarker... 
Hematology, Oncology and Palliative Medicine | Hypertension | Single-nucleotide polymorphism | Bevacizumab-associated toxicity | FOLFIRI/bevacizumab | Autophagy | Colorectal cancer | APOPTOSIS | INHIBITION | ONCOLOGY | SENESCENCE | STRESS | PLUS BEVACIZUMAB | PROGRESSION | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - administration & dosage | Bevacizumab - adverse effects | Humans | Middle Aged | Genotype | Male | Neoplasm Metastasis | Protein-Tyrosine Kinases - genetics | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - drug therapy | Hypertension - chemically induced | Polymorphism, Single Nucleotide - genetics | Adult | Camptothecin - administration & dosage | Cetuximab - administration & dosage | Female | Aged | Autophagy - genetics | Chemotherapy, Adjuvant | Camptothecin - analogs & derivatives | Genetic aspects | Metastasis | Single nucleotide polymorphisms | Thromboembolism | Vascular endothelial growth factor | Medicine, Preventive | Preventive health services | Measurement | Endothelial growth factors | Blood pressure | Toxicity | Genes | Colorectal carcinoma | Clinical trials | Patients | Two phase | Bleeding | Bevacizumab | Metastases | Confidence intervals | Angiogenesis | Alleles | Phagocytosis | Genotypes | Polymorphism | Proteinuria | Cancer | Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 03/2018, Volume 13, Issue 3, pp. e0193640 - e0193640
Journal Article
International Journal of Cancer, ISSN 0020-7136, 09/2017, Volume 141, Issue 6, pp. 1222 - 1230
The TLR7 and TLR9 signalings are implicated in the regulation of the immune system through type‐I interferon induction. Preclinical studies have demonstrated... 
cetuximab | metastatic colorectal cancer | polymorphism | TLR7 | predictive marker | SYSTEMIC-LUPUS-ERYTHEMATOSUS | ANTIBODY | IFN-ALPHA PRODUCTION | RECEPTOR 7 | PLASMACYTOID DENDRITIC CELLS | SEX-SPECIFIC ASSOCIATION | IMMUNE | THERAPY | ONCOLOGY | INFLAMMATION | INDEPENDENTLY CONTRIBUTE | Leucovorin - administration & dosage | Predictive Value of Tests | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | RNA, Messenger - biosynthesis | Clinical Trials, Phase III as Topic | Neoplasm Metastasis | Fluorouracil - administration & dosage | Multicenter Studies as Topic | Colorectal Neoplasms - drug therapy | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Toll-Like Receptor 7 - genetics | Toll-Like Receptor 7 - biosynthesis | RNA, Messenger - genetics | Randomized Controlled Trials as Topic | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cetuximab - administration & dosage | Aged | Polymorphism, Single Nucleotide | Colorectal Neoplasms - pathology | Clinical Trials, Phase II as Topic | Cancer patients | Care and treatment | Chemotherapy | Analysis | Colorectal cancer | Genetic aspects | Interferon | Single nucleotide polymorphisms | Metastasis | Biological response modifiers | Chromosomes | Cancer | Colorectal carcinoma | Single-nucleotide polymorphism | K-Ras protein | Bevacizumab | Metastases | Gene sequencing | Anticancer properties | Toll-like receptors | Deoxyribonucleic acid--DNA | Immune system | Killing | TLR7 protein | Immunomodulation | Genetic diversity | Patients | TLR9 protein | Polymerase chain reaction | Interferon regulatory factor 7 | Studies | Antitumor activity | Death | DNA sequencing | Polymorphism | Index Medicus
Journal Article